Introduction
A joint initiative by KPMG and EuroCham Vietnam:
As Vietnam’s healthcare industry enters a new stage of growth, KPMG and the European Chamber of Commerce (EuroCham) have joined forces to provide a forward-looking perspective on the future of the generics market.
This collaboration combines KPMG’s strategic insights and economic modelling with EuroCham’s deep understanding of the policy and regulatory environment affecting European and Vietnamese pharmaceutical stakeholders. Together, the two organizations aim to highlight both the opportunities and the practical challenges that lie ahead — from navigating new regulations and EU-GMP compliance, to building public trust in generic medicines.
The report not only presents data and projections, but also a roadmap for action — guiding policymakers, investors, and industry leaders toward a more affordable, transparent, and competitive healthcare ecosystem for Vietnam.
Vietnam’s Generics Market: Building a Sustainable Future for Affordable Care
Vietnam’s healthcare system is evolving quickly — but rising costs and an aging population are stretching its limits. Generic medicines offer a practical answer: quality treatment at a fraction of the cost. Yet barriers in regulation, investment, and perception continue to slow progress.
This KPMG–EuroCham report provides a grounded view of where the market stands and what needs to change — from streamlining drug approvals to supporting EU-GMP manufacturing and increasing trust among doctors and patients. With the right reforms, Vietnam can ensure affordable access to care while developing a globally competitive pharmaceutical base.
Vietnam stands at a pivotal moment in the evolution of its healthcare sector. As the country undergoes rapid economic transformation, ensuring access to high-quality, affordable medicines remains a critical priority. The generic pharmaceutical industry has a vital role to play in meeting this need by offering cost-effective alternatives that maintain the highest standards of safety and efficacy.
How policy reform and investment can turn Vietnam into a regional pharmaceutical hub
The next phase of growth for Vietnam’s generics market will depend on clarity, consistency, and confidence. Simplifying registration processes, incentivizing local production, and aligning with international standards can close the current USD 3.8 billion import gap and unlock new export opportunities.
But technical reform alone is not enough. Building trust — from policymakers to prescribers to patients — is equally critical. This report outlines actionable lessons from Australia, Singapore, and Poland, showing how coordinated reform can help Vietnam strengthen its domestic industry and take a leading role in the region’s affordable healthcare supply chain.
Future Value of Vietnam’s Generics Market 2025
Insights from KPMG & EuroCham on advancing affordable, high-quality healthcare in Vietnam.
Download English PDF (10.7 MB) ⤓
Download Vietnamese PDF (10.9 MB) ⤓
